Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third ...
July 25 2017 - 4:00PM
Business Wire
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that it plans to report its financial results for its
fiscal third quarter ended June 30, 2017, after the U.S. markets
close on August 7, 2017. Enanta management will host a conference
call at 4:30 p.m. ET to discuss these results and provide an update
on Enanta’s business, including its research and development
pipeline.
Conference Call and Webcast InformationTo participate in
the live conference call, please dial (855) 840-0595 in the U.S. or
(518) 444-4814 for international callers. A replay of the
conference call will be available starting at approximately 7:30
p.m. ET on August 7, 2017, through 11:59 p.m. ET on August 10, 2017
by dialing (855) 859-2056 from the U.S. or (404) 537-3406 for
international callers. The passcode for both the live call and the
replay is 47670579. A live audio webcast of the call and replay can
be accessed by visiting the “Events and Presentation” section on
the “Investors” page of Enanta’s website at www.enanta.com.
About EnantaEnanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs for viral infections and liver diseases.
Enanta’s research and development efforts are currently focused on
the following disease targets: non-alcoholic steatohepatitis
(NASH)/ primary biliary cholangitis (PBC), respiratory syncytial
virus (RSV) and hepatitis B virus (HBV). Enanta has also discovered
novel protease inhibitors that have been developed as part of
AbbVie’s hepatitis C virus (HCV) treatment regimens under a
collaboration that now provides Enanta a payment stream, which it
is using to fund its research and development programs. Please
visit www.enanta.com for more information on Enanta’s programs and
pipeline.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170725005229/en/
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024
